Home › Macular Degeneration › Virginia
Macular Degeneration clinical trials in Virginia
7 studies for Macular Degeneration are looking for participants at sites in Virginia.
Cities in Virginia
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- Piedmont Eye Center (Site 054), Lynchburg
RecruitingPhase 2/3
Ages 50 and older · All sexes · Updated Oct 2, 2026 · NCT07440225A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Piedmont Eye Center, Lynchburg
- Wagner Kapoor Research institute, Norfolk
RecruitingPhase 2/3
Ages 60 and older · All sexes · Updated Sep 30, 2026 · NCT06635148A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- Southeastern Retina Associates, Bristol
- Retina Group of Washington, Fairfax
- Piedmont Eye Center, Lynchburg
- and 1 more
RecruitingPhase 3
Ages 50 to 85 · All sexes · Updated Sep 18, 2026 · NCT06541704Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
- Piedmont Eye Center, Lynchburg
RecruitingPhase 2
Ages 55 and older · All sexes · Updated Sep 10, 2026 · NCT06659445A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
- Wagner Macula & Retina Center, Norfolk
RecruitingObservational study
Ages 50 and older · All sexes · Updated Sep 1, 2026 · NCT06346600A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- Vistar Eye Center (Site 129), Roanoke
RecruitingPhase 2/3
Ages 50 and older · All sexes · Updated Aug 6, 2026 · NCT07496567Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Piedmont Eye Center, Lynchburg
RecruitingPhase 3
Ages 50 and older · All sexes · Updated Apr 16, 2026 · NCT07064759From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.